Across TCGA pan-cancer cohorts, TP53TG5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TP53TG5 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher TP53TG5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TP53TG5 expression acts as an unfavorable survival marker.
READ, SKCM, and PRAD are the cancer types where TP53TG5 Mutation most reproducibly stratifies survival.